These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30099637)

  • 1. Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
    Vehreschild MJGT; Taori S; Goldenberg SD; Thalhammer F; Bouza E; van Oene J; Wetherill G; Georgopali A
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2097-2106. PubMed ID: 30099637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection.
    Spiceland CM; Khanna S; Pardi DS
    J Clin Gastroenterol; 2018 Feb; 52(2):151-154. PubMed ID: 28009682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of using fidaxomicin on recurrent Clostridium difficile infection.
    Biggs M; Iqbal T; Holden E; Clewer V; Garvey MI
    J Hosp Infect; 2019 Jun; 102(2):165-167. PubMed ID: 30615960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is shorter also better in the treatment of Clostridioides difficile infection?
    Duricek M; Halmova K; Krutova M; Sykorova B; Benes J
    J Antimicrob Chemother; 2024 Jun; 79(6):1413-1417. PubMed ID: 38661207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia.
    Novotný M; Jarčuška P; Gombošová L; Hockicko J; Hockicková I; Rovňáková A; Zahornacký O; Schréter I; Dorko E; Rimárová K
    Cent Eur J Public Health; 2018 Dec; 26 Suppl():S76-S80. PubMed ID: 30817879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.
    Zhao Z; Wu Y; Geng X; Yuan C; Fu Y; Yang G
    Medicine (Baltimore); 2024 Aug; 103(32):e39213. PubMed ID: 39121324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
    Vehreschild MJGT; Taori S; Goldenberg SD; Thalhammer F; Bouza E; van Oene J; Wetherill G; Georgopali A
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):199. PubMed ID: 30406879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE).
    Högenauer C; Mahida Y; Stallmach A; Marteau P; Rydzewska G; Ivashkin V; Gargalianos-Kakolyris P; Michon I; Adomakoh N; Georgopali A; Tretter R; Karas A; Reinisch W
    J Antimicrob Chemother; 2018 Dec; 73(12):3430-3441. PubMed ID: 30260412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and microbiological characteristics of Clostridium difficile infection in children hospitalized at the Departement of Paediatric Infectious Diseases in Brno between 2013 and 2017.
    Musil V; Homola L; Vrba M; Braunová A; Malá M; Holečková P; Krbková L
    Epidemiol Mikrobiol Imunol; 2019; 68(1):15-22. PubMed ID: 31181948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease.
    Gupta A; Wash C; Wu Y; Sorrentino D; Nguyen VQ
    Dig Dis Sci; 2021 Feb; 66(2):547-553. PubMed ID: 32207033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
    Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
    J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
    Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ
    Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
    Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
    J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease.
    Koop AH; Travers PM; Khanna S; Pardi DS; Farraye FA; Hashash JG
    J Gastroenterol Hepatol; 2023 Nov; 38(11):1910-1916. PubMed ID: 37337469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.